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Summary, discussion and perspectives
CLL and MCL are two types of small cell lymphoma for which no effective treatment 
protocols exist. The mainstays of the treatment for these lymphomas are varying 
between a “wait and see” or monochemotherapy in the indolent form of CLL to 
polychemotherapy combined with molecular therapy followed by allogeneic stem cell 
rescue  or even allogeneic stem cell transplantation in MCL. However, many of these 
modalities have limitations because of severe side effects and limited capacities to 
discriminate between healthy and cancerous cells, which are in particular relevant 
since both diseases mainly affect elderly patients with a limited capacity to recover 
from these therapies. 
Research on signal transduction pathways and key players therein can contribute to 
our understanding of the molecular individual cancers, the identification of possible 
molecular targets for pharmacological inhibitors or activators, and thus might lead to 
novel therapeutic strategies and molecular therapies. 
MiRNAs are a new group of regulators relatively recently discovered which have 
been shown to play important roles in the pathogenesis of cancer by regulating both 
oncogenes and tumor suppressor genes.
This thesis focuses on the signal transduction profile and miRNA expression of these 
two diseases.
Part 1:  Kinases
In this part, we investigated the role of kinases in CLL and MCL. Signaling through 
BCR and CD40L are the most important signal transduction pathways in B cells and 
also play an important role in B cell malignancies. In these two signaling pathways, 
the mitogen-activated protein kinases (MAPK) are an extensively studied group of 
protein kinases, as reviewed in chapter 1.
Kinome profiling is an array-based method to identify all active kinases in cells by 
monitoring phosphorylation of consensus peptides1. This method is an efficient tool 
to compare the whole kinome between different groups of samples. Based on the 
notion that most kinase inhibitors have broad kinase inhibition functions,  kinome 
profiling can be used to study the mechanisms of kinase inhibitors by comparing  the 
kinase activity between an uninhibited and inhibited population of cells2;3. By using 
this method, we compared the kinase activity between ZAP-70+ CLL cells and ZAP-
70- cases (chapter 2). We found that there is higher kinase activity of Syk in ZAP-
70+ cases. These findings were confirmed by conventional techniques. Furthermore, 
Syk inhibition can lead to apoptosis in cell lines as well as patient samples, so Syk 
could be a potential therapy target for CLL cells. Syk is a protein tyrosine kinase 
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which plays an important role in the initiation of signaling from the B-cell receptor 
(BCR)4. Syk is required for the survival of many kinds of B cell lymphomas and has 
been identified as a treatment target for several lymphomas such as diffuse large B cell 
lymphoma (DLBCL), MCL, Burkitt lymphoma (BL) and follicular lymphoma (FL)5-8. 
MAPK signal transduction is very important for cell proliferation and cell cycle 
progression and has become an important target in many kinds of cancers9;10. In 
chapter 2, we found that there were higher kinase activities of JNK and S6K in ZAP-
70+ cases compared to ZAP-70-cases. JNK inhibition with SP600125 induced G2/M 
cell cycle arrest and inhibition of S6K through rapamycin led to G0/G1 arrest in cell 
lines. Recently, Decker11  et al reported a phase II  trial with the oral rapamycin RAD001 
in seven patients with advanced B-CLL. After two cycles of treatment, one patient was 
in partial on remission and three patients had stable disease. Thus, targeting the cell 
cycle can be an attractive therapeutic approach for CLL .
In chapter 3, we identify Raf-1 as a critical anti-apoptotic and cell cycle regulation 
kinase in CLL cells, by activating the p-ERK and p-BAD pathways. By using specific 
inhibitors, we demonstrated that Raf-1 is also important for G0/G1 cell cycle progression 
by regulation of cyclin D3 and cyclin E. By Annexin V staining, we found that GW5074 
can lead to apoptosis of CLL cells, both in cell lines and patient samples. Raf-1 
inhibition could thus be an important therapy target for CLL.  The methods of targeting 
Raf-1 in cancer include antisense oligodeoxynucleotides (ASON) and Raf-1 inhibitors 
(GW5074) or destabilizers (Geldanamycin). The anti-tumor activity of ASON has been 
evaluated in phase II studies in patients with ovarian, small-cell lung and non–small-
cell lung carcinomas. The strategy to be used in CLL to target Raf-1  needs to be 
further studied12. 
In comparison with normal tonsil B cells, we identified JNK as an important MAPK in 
MCL cells (chapter 4). Inhibition of JNK with SP600125 resulted in G2-M phase arrest 
on day 1 and a strikingly increased endoreduplication on day 2 and day 3, which was 
confirmed by karyotype analysis. G2-M arrest was associated with downregulation of 
EGR1. SP600125 induced polyploidy, that could be blocked by the BCL-2 inhibitor 
YC 137. These data suggest that constitutive JNK activity is necessary to promote 
proliferation and maintain diploidy in MCL and that disruption of this MAPK leads to a 
profound cell cycle deregulation and endoreduplication. Our data also provide a model 
to study polyploid MCL cells.
We found that Syk inhibition can lead to apoptosis in CLL cells. Rinaldi 13et al showed 
that Syk is over-expressed in MCL and constitutes a possible treatment target for MCL. 
We investigated the mRNA expression level in eleven B cell lines and found that Syk 
is highly expressed in MCL cell lines (Figure 1). The function of Syk in MCL can be 
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studied in MCL cell lines, the effect of Syk inhibition in MCL needs to be studied in 
primary cases.
We found that Raf-1 is overexpressed in CLL and that inhibition of Raf-1 can lead to 
apoptosis of CLL cells. Since overexpression of Raf-1 at the mRNA level is associated 
with a bad prognosis in MCL14, it is interesting to gain insight into the function of Raf-1 
kinase in this disease. Our results also showed that Raf-1 inhibition can lead to cell 
cycle arrest by downregulating cyclin D3 and cyclin E expression in CLL cell lines. 
In MCL, where cyclin D1 is overexpressed due to the t (11, 14) translocation, Raf-1 
inhibition may only be effective if it leads to degradation of cyclin D1. 
Part 2:  miRNA
In this part, we analyzed miRNA expression in CLL and normal B cell subsets. 
Recent studies have shown that miRNAs play an important role in normal B cell 
differentiation and  affect the prognosis of CLL, however, there is some controversy 
which may have been caused by  different experimental methods. We reviewed the 
miRNA study methods and recent miRNA studies in CLL (chapter 5). The miRNA 
field has grown exponentially and many CLL related miRNAs have been identified. To 
solve the problem of discordant results in CLL, several factors should be taken into 
account. First, as different results can be generated from different methods, miRNA 
study methods should be improved and standardized. Second, miRNA expression 
is usually tissue specific and individual miRNAs may have a different function in 
different tissues. Thus, miRNA expression studies in cancer samples should also 
compare the normal tissues as counterpart, which would help in defining those 
miRNAs that are functionally significant. 
Figure 1: Syk mRNA expression in B cell lines
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In chapter 6, we analyzed the expression of fifteen miRNAs in thirty-three lymph 
nodes and thirty-seven blood samples of CLL patients. There were similar miRNA 
expression patterns in the lymph node and blood samples and three miRNAs (miR-
16, miR-21 and miR-150) showed a high expression level in all samples. Contrary to 
some reports, we did not find a correlation between miRNA expression and ZAP-70/
VH mutation status, which might be due to the different detection methods15;16. Our 
RNA in situ hybridization (ISH) experiments revealed a strong homogeneous staining 
of miR-150 in the tumor cells but a very weak staining within the proliferation centers, 
which are a hallmark of CLL. In reverse BIC/pri-miR-155 expression was observed 
mainly in individual cells including prolymphocytes of the proliferation centers. This 
reciprocal pattern likely reflects the different functions and targets of miR-150 and 
miR-155. Recent reports in transgenic mouse models showed that miR-150 plays a 
key role in B cell differentiation by targeting c-myb and foxp1 protein expression17;18. 
Ectopic expression of miR-150 in breast cancer and leukemic cells repressed 
endogenous c-Myb at both the mRNA and protein levels, which shows that c-Myb is 
an evolutionary conserved target of miR-15019. The function of miR-150 in CLL needs 
to be further studied.
In chapter 7, we identified some miRNAs that are differentialy expressed in three 
subsets of B cells (naïve B cells, germinal center B cells and memory B cells) by 
miRNA profiling. Naive and memory B cells had very similar expression patterns, 
which were different from germinal center B cells. These findings were confirmed by 
RNA in situ hybridization (ISH). MiR-150 was the most obvious discriminatory marker 
for GC and non-GC B cells. By transfecting the precursor of miR-150, we confirmed 
that c-Myb and Foxp1 are targets and found that miR-150 plays an important role in 
cell proliferation by regulating survivin expression.
The potentially most interesting observation was that RNA in situ hybridization (ISH) 
revealed a low expression of miR-150 and high expression of BIC (the precursor 
of miR-155) in the PCs in CLL. In CLL, the neoplastic cells in these structures are 
more activated than the surrounding neoplastic cells and circulating cells with an 
active BCR or CD40L signaling pathway. So it would be interesting to correlate the 
expression and function of miR-150 and BIC with BCR and CD40L signaling. We 
analyzed the change in miR-150 expression after IgM stimulation in purified B cells 
of three tonsils and three CLL cases. After IgM stimulation for 6 hours, miR-150 
expression was downregulated in two CLL cases, whereas no obvious changes were 
found in another case and in the tonsil B cells. 
We also need to investigate the BIC/miR-155 expression after IgM stimulation. We 
should correlate the changes in miRNA expression levels with a proteomics study to 
find the targets of a specific miRNA. 




Our studies demonstrate that deregulation of the kinase activity and miRNAs is 
involved in the pathogenesis of lymphomas and leukemias. Thus, an important step 
for future studies is to introduce specific kinase inhibitors, anti-miRNA or pre-miRNA 
oligonucleotides into clinical trials. However, there are a few obstacles that need to 
be considered. 
The first obstacle is the question whether the selected targets are essential or not for 
kinase inhibition and to what extend redundancy exists. It is tempting to speculate 
on the future application of MAP kinase inhibitors in clinical lymphoma treatment. 
The design of kinase inhibitors is difficult because there is much cross-talk between 
the MAPK pathways as well as double-edged functions. For instance, different 
functions (targeting apoptosis and proliferation) have been ascribed to the three 
MAPK - ERK, JNK and p38. Piceatannol was already identified as a tyrosine kinase 
inhibitor in 1989 20. However, it can also lead to apoptosis of human leukemic U937 
cells by downregulation of Bcl-2 and activation of caspases21. Because of its anti-
proliferative property, Sorafenib (BAY 43-9006) has been developed as an inhibitor 
of RAF kinase. However, it also inhibits receptor tyrosine kinases of multiple pro-
angiogenic factors such as VEGFR-2/3, Flt-3/ and PDGFR-beta22. 17-N-Allylamino-
17-demethoxygeldanamycin (17-AAG) binds to Hsp90 and alters levels of proteins 
regulated by Hsp90. Hsp90 is not only the chaperone for Raf-1 and Bcl-2, but also 
for many other molecules important for cell survival and cell cycle progression, such 
as p53, survivin and c-myc23-25. SP600125 has been identified as a specific inhibitor 
of JNK, but also inhibits voltage dependent K+ channels in a JNK-independent way26. 
Thus, improvements in specific kinase inhibitor design and development are still very 
much needed. Another fact is that kinase activity is also regulated by phosphatases. 
Figure 2: miR-150 expression before and after IgM stimulation
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Thus, targeting phosphatases is also a method to regulate MAPK signaling27.  
MiRNAs can function not only as a tumor suppressor gene but also as oncogene by 
their posttranscriptional regulatory functions. Thus, miRNAs can be used as drugs or 
as therapy targets. The advantage but possibly also the disadvantage of miRNAs as 
a focus for research on novel drugs is the fact that many miRNAs are tissue specific 
and miRNAs may have different functions in different tissues.  Furthermore, there 
may be many interactions between individual miRNAs. Therefore, it may be difficult 
to qualify a particular miRNA as a specific drug or drug target.
Another obstacle is drug resistance and safety concerns. The selective inhibition 
of protein kinases becomes more and more important as an effective therapeutic 
approach. Imatinib is a specific inhibitor of a number of tyrosine kinase enzymes and 
is used to decrease bcr-abl activity which is caused by the Philadelphia chromosome. 
However, clinical resistance caused by mutations in the targeted oncogene has been 
observed, especially in imatinib-treated leukaemia patients28. Based on the concerns 
about the toxicity of RNAi29, we can imagine that a main concern in miRNA treatment 
will also be safety. Thus, mechanistic studies are still very important to test and 
develop new ideas for treatment.
References
 1.  Diks S, Kok K, O’Toole T et al. Kinome Profiling for Studying Lipopolysaccharide Signal Transduction 
in Human Peripheral Blood Mononuclear Cells. J.Biol.Chem. 2004;279:49206-49213.
 2.  Tuynman J, Vermeulen L, Boon E et al. Cyclooxygenase-2 Inhibition Inhibits c-Met Kinase Activity 
and Wnt Activity in Colon Cancer. Cancer Res 2008;68:1213-1220.
 3.  Brazil M. Surveying the kinome. Nat Rev Drug Discov 2005;4:279.
 4.  Cornall RJ, Cheng AM, Pawson T, Goodnow CC. Role of Syk in B-cell development and antigen-
receptor signaling. Proc.Natl.Acad.Sci.U.S.A 2000;97:1713-1718.
 5.  Leseux L, Hamdi S, al Saati T et al. Syk-dependent mTOR activation in follicular lymphoma cells. 
Blood 2006;108:4156-4162.
 6.  Gururajan M, Dasu T, Shahidain S et al. Spleen Tyrosine Kinase (Syk), a Novel Target of Curcumin, 
Is Required for B Lymphoma Growth. J Immunol 2007;178:111-121.
 7.  Chen L, Juszczynski P, Takeyama K, Aguiar R, Shipp M. Protein tyrosine phosphatase receptor-
type O truncated (PTPROt) regulates SYK phosphorylation, proximal B-cell-receptor signaling, 
and cellular proliferation. Blood 2006;108:3428-3433.
 8.  Braselmann S, Taylor V, Zhao H et al. R406, an Orally Available Spleen Tyrosine Kinase Inhibitor 
Blocks Fc Receptor Signaling and Reduces Immune Complex-Mediated Inflammation. J 
Pharmacol Exp Ther 2006;319:998-1008.
 9.  Sebolt-Leopold JS. Blockade of the MAP kinase pathway suppresses growth of colon tumors in 
vivo. Nat.Med. 1999;5:810-816.
 10.  Sebolt-Leopold JS. Development of anticancer drugs targeting the MAP kinase pathway. 
Oncogene 2000;19:6594-6599.
thesis book.indb   141 05/11/2008   13:42:02
 11.  Decker T, Sandherr M, Goetze K et al. A pilot trial of the mTOR (mammalian target of rapamycin) 
inhibitor RAD001 in patients with advanced B-CLL. Ann.Hematol. 2008
 12.  Cripps MC, Figueredo A, Oza A et al. Phase II Randomized Study of ISIS 3521 and ISIS 5132 
in Patients with Locally Advanced or Metastatic Colorectal Cancer: A National Cancer Institute of 
Canada Clinical Trials Group Study. Clin Cancer Res 2002;8:2188-2192.
 13.  Rinaldi A, Kwee I, Taborelli M et al. Genomic and expression profiling identifies the B-cell associated 
tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. Br.J Haematol. 
2006;132:303-316.
 14.  Nagy B, Galimberti S, Benedetti E et al. RAF-1 over-expression does condition survival of patients 
affected by aggressive mantle cell lymphoma. Leukemia Research 2007;31:1595-1597.
 15.  Calin GA, Ferracin M, Cimmino A et al. A MicroRNA signature associated with prognosis and 
progression in chronic lymphocytic leukemia. N.Engl.J Med. 2005;353:1793-1801.
 16.  Calin GA, Liu CG, Sevignani C et al. MicroRNA profiling reveals distinct signatures in B cell chronic 
lymphocytic leukemias. Proc.Natl.Acad.Sci.U.S.A 2004;101:11755-11760.
 17.  Xiao C, Calado DP, Galler G et al. MiR-150 controls B cell differentiation by targeting the 
transcription factor c-Myb. Cell 2007;131:146-159.
 18.  Zhou B, Wang S, Mayr C, Bartel DP, Lodish HF. miR-150, a microRNA expressed in mature B and 
T cells, blocks early B cell development when expressed prematurely. Proc.Natl.Acad.Sci.U.S.A 
2007;104:7080-7085.
 19.  Lin YC, Kuo MW, Yu J et al. MiR-150 negatively regulates c-Myb expression, which is evolutionarily 
conserved and plays an important role in developmental process. Mol.Biol.Evol. 2008
 20.  Geahlen R, McLaughlin J. Piceatannol (3,4,3’,5’-tetrahydroxy-trans-stilbene) is a naturally 
occurring protein-tyrosine kinase inhibitor. Biochemical and Biophysical Research Communications 
1989;165:241-245.
 21.  Kim YH, Park C, Lee JO et al. Induction of apoptosis by piceatannol in human leukemic U937 cells 
through down-regulation of Bcl-2 and activation of caspases. Oncol.Rep. 2008;19:961-967.
 22.  Ng R, Chen EX. Sorafenib (BAY 43-9006): review of clinical development. Curr.Clin.Pharmacol. 
2006;1:223-228.
 23.  Peng Y, Chen L, Li C, Lu W, Chen J. Inhibition of MDM2 by hsp90 Contributes to Mutant p53 
Stabilization. J.Biol.Chem. 2001;276:40583-40590.
 24.  Carystinos G, Kandouz M, Alaoui-Jamali M, Batist G. Unexpected Induction of the Human 
Connexin 43 Promoter by the Ras Signaling Pathway Is Mediated by a Novel Putative Promoter 
Sequence. Mol Pharmacol 2003;63:821-831.
 25.  Fortugno P, Beltrami E, Plescia J et al. Regulation of survivin function by Hsp90. Proc.Natl.Acad.
Sci.U.S.A 2003;100:13791-13796.
 26.  Martial S, Giorgelli J, Renaudo A, Derijard B, Soriani O. SP600125 inhibits Kv channels through a 
JNK-independent pathway in cancer cells. Biochemical and Biophysical Research Communications 
2008;366:944-950.
 27.  Jeffrey K, Camps M, Rommel C, Mackay C. Targeting dual-specificity phosphatases: manipulating 
MAP kinase signalling and immune responses. Nat Rev Drug Discov 2007;6:391-403.
 28.  Bubnoff Nv, Peschel C, Duyster J. Resistance of Philadelphia-chromosome positive leukemia 
towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back. 
Leukemia 0 AD;17:829-838.
 29.  Frantz S. Safety concerns raised over RNA interference. Nat Rev Drug Discov 2006;5:528-529.
thesis book.indb   142 05/11/2008   13:42:02
